Biomerica, Inc.
BMRA · NASDAQ
11/30/2025 | 8/31/2025 | 5/31/2025 | 2/28/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -10.13 | -0.04 | -0.97 |
| FCF Yield | -14.52% | -3.24% | -2.23% | -1.04% |
| EV / EBITDA | -3.56 | 52.14 | -18.95 | -88.35 |
| Quality | ||||
| ROIC | -29.10% | -8.09% | -34.28% | -19.84% |
| Gross Margin | 4.21% | 30.72% | -32.58% | 1.70% |
| Cash Conversion Ratio | 0.75 | -134.00 | 0.43 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.76% | -3.38% | -0.18% | -15.86% |
| Free Cash Flow Growth | -255.97% | 59.46% | 36.75% | -32.11% |
| Safety | ||||
| Net Debt / EBITDA | 1.86 | -25.05 | 1.33 | 2.26 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.76 | 0.65 | 0.67 | 0.66 |
| Cash Conversion Cycle | 131.32 | 153.15 | 196.15 | 185.68 |